MedPath

Trial to Evaluate Effect of Lactulose on Hard Stools in Patients With Hemorrhoids or Anal Fissures

Phase 4
Terminated
Conditions
Hemorrhoids
Anal Fissures
Interventions
Registration Number
NCT00160290
Lead Sponsor
Solvay Pharmaceuticals
Brief Summary

To demonstrate that lactulose acts as a stool softener, relieving the pain at defecation, improving the number of defecations and regulating the colonic transit time in patients suffering of hemorrhoids or anal fissure. To compare efficacy and quality of life in patients treated either with lactulose or plantago ovate.

Detailed Description

Not available

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
97
Inclusion Criteria
  • Patients suffering from symptomatic hemorrhoids, or symptomatic anal fissure.
Exclusion Criteria
  • Patients suffering from malignant tumor in the intestine or the anal-rectal region, irritable colon, intestine inflammatory disease.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
ALactuloseLactulose Group
BPlantago ovataPlantago Group
Primary Outcome Measures
NameTimeMethod
Quality of life of patients with hard stools and hemorrhoids or anal fissure6 weeks
Secondary Outcome Measures
NameTimeMethod
Gastrointestinal Symptoms Rating Scale6 weeks
Bristol stool consistency scale6 weeks
Number of episodes of rectal bleeding6 weeks
Need of rescue medication6 weeks

Trial Locations

Locations (8)

Site 2

🇪🇸

Barcelona, Spain

Site 6

🇪🇸

Granada, Spain

Site 5

🇪🇸

Huesca, Spain

Site 7

🇪🇸

Oviedo, Spain

Site 4

🇪🇸

Sabadell (Barcelona), Spain

Site 3

🇪🇸

Sant Cugat del Vallès (Barcelona), Spain

Site 8

🇪🇸

Santiago de Compostela, Spain

Site 1

🇪🇸

Valencia, Spain

Site 2
🇪🇸Barcelona, Spain

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.